Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. - Raut SB; Marathe PA; van Eijk L; Eri R; Ravindran M; Benedek DM; Ursano RJ; Canales JJ; Johnson LR (Pharmacology & therapeutics, 2022)

Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis. - Berens N; Kim SY (The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry, 2022)

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. - Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L (Psychopharmacology, 2022)

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. - Henningfield JE; Coe MA; Griffiths RR; Belouin SJ; Berger A; Coker AR; Comer SD; Heal DJ; Hendricks PS; Nichols CD; Sapienza F; Vocci FJ; et al. (Neuropharmacology, 2022)

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. - Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA (Addiction biology, 2022)

Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer. - Patchett-Marble R; O'Sullivan S; Tadwalkar S; Hapke E (Canadian family physician Medecin de famille canadien, 2022)

Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. - Schindler EAD; Sewell RA; Gottschalk CH; Luddy C; Flynn LT; Zhu Y; Lindsey H; Pittman BP; Cozzi NV; D'Souza DC (Headache, 2022)

Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. - Irizarry R; Winczura A; Dimassi O; Dhillon N; Minhas A; Larice J (Cureus, 2022)

A Rare Case of Magic Mushroom (Psilocybin) Related AKI and Hypertensive Emergency - Syed Rizwan A. Bokhari; Ahmad Makmom Abdullah; Zamir A. Zamir; Raquel M. Rosen (Journal of the American Society of Nephrology, 2022)

Kan psilocybin forbedre vores moral? - Victor Lange; Marie; Sidsel (Research at the University of Copenhagen (University of Copenhagen), 2022)

What Are Magic Mushrooms? Why They Are Popular In British Columbia - b2xvysw192 (Zenodo (CERN European Organization for Nuclear Research), 2022)

Psychedelics for Use and Wellbeing Cultural Context and Recent Developments: A Jamaican Perspective - Winston De La Haye (Online Journal of Complementary & Alternative Medicine, 2022)

Serotonergic antidepressant use is associated with weaker psilocybin effects - Gukasyan N; Griffiths RR; Yaden DB; Antoine D; Nayak SM. (PsyArXiv, 2022)

Serotonergic antidepressant use is associated with weaker psilocybin effects - Natalie Gukasyan; Roland R. Griffiths; David Bryce Yaden; Denis Antoine; Sandeep M Nayak (PsyArXiv, 2022)

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. - Sheppard Pratt Health System (ClinicalTrials.gov, 2022)

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial - Stefan Baumann; Robin Carhart-Harris; David Nutt; David Erritzoe (PsyArXiv, 2022)

Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity. - Gaddis A; Lidstone DE; Nebel MB; Griffiths RR; Mostofsky SH; Mejia AF; Barrett FS (NeuroImage, 2022)

Psilocybin treatment for AUD: Promise in new study - Alison Knopf (Alcoholism & Drug Abuse Weekly, 2022)

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). - Jensen ME; Stenbæk DS; Juul TS; Fisher PM; Ekstrøm CT; Knudsen GM; Fink-Jensen A (BMJ open, 2022)

An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) - Beckley Psytech Limited (ClinicalTrials.gov, 2022)

Fungal Hallucinogens: Chemistry, Synthesis, Behavior, Toxicity and Detection Methods in Forensic Perspective - Merlin Kirubakarababu; Arputharaj Samson Nesaraj (Indian Journal of Forensic Medicine & Toxicology, 2022)

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. - Jones GM; Nock MK (Scientific reports, 2022)

Psilocybin: a revolution in psychedelic medicines in the US? - Silberner J (BMJ (Clinical research ed.), 2022)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355 - Ching THW; Kichuk S; DePalmer G; Pittenger C; Kelmendi B. (PsyArXiv, 2022)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355 - Terence Ching; Stephen Kichuk; Giuliana DePalmer; Christopher Pittenger; Benjamin Kelmendi (PsyArXiv, 2022)

Conformational Landscape and Properties of Psilocybin: A Computational Approach - Poonam Bhadoria; V. Ramanathan (ChemistrySelect, 2022)

Psilocybin for Treatment of Alcohol Use Disorder. - Slomski A (JAMA, 2022)

Group Format Psilocybin-Assisted Therapy: Commentary on the HOPE trial (HOPE: a pilot study of psilocybin-enhanced group psychotherapy in patients with cancer) - Benjamin R. Lewis; Kevin Byrne; Anna C. Beck (Journal of Anesthesiology and Pain Therapy, 2022)

Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. - Singleton SP; Luppi AI; Carhart-Harris RL; Cruzat J; Roseman L; Nutt DJ; Deco G; Kringelbach ML; Stamatakis EA; Kuceyeski A (Nature communications, 2022)

Chinese Cordyceps: Bioactive Components, Antitumor Effects and Underlying Mechanism-A Review. - Liu Y; Guo ZJ; Zhou XW (Molecules (Basel, Switzerland), 2022)

19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations - Natalie Gukasyan (Journal of the American Academy of Child & Adolescent Psychiatry, 2022)

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. - Timmermann C; Watts R; Dupuis D (Transcultural psychiatry, 2022)

If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. - Dworkin RH; Anderson BT; Andrews N; Edwards RR; Grob CS; Ross S; Satterthwaite TD; Strain EC (The journal of pain, 2022)

Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin. - Meyer TD; Meir P; Lex C; Soares JC (Psychiatry research, 2022)

Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. - Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM (Expert opinion on drug discovery, 2022)

Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. - Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J (Current psychiatry reports, 2022)

Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. - Levin A; Nagib PB; Deiparine S; Gao T; Mitchell J; Davis AK (The International journal on drug policy, 2022)

Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. - Barnett BS; Ziegler K; Doblin R; Carlo AD (Journal of psychopharmacology (Oxford, England), 2022)

New investigational agents for the treatment of major depressive disorder. - Pochwat B; Krupa AJ; Siwek M; Szewczyk B (Expert opinion on investigational drugs, 2022)

Prevalence and associations of classic psychedelic-related seizures in a population-based sample. - Simonsson O; Goldberg SB; Chambers R; Osika W; Long DM; Hendricks PS (Drug and alcohol dependence, 2022)

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. - Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; et al. (JAMA psychiatry, 2022)

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. - Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA (Journal of psychopharmacology (Oxford, England), 2022)

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives. - Kaypak AC; Raz A (Transcultural psychiatry, 2022)

Serotonin 5-HT, 5-HT and 5-HT receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. - Erkizia-Santamaría I; Alles-Pascual R; Horrillo I; Meana JJ; Ortega JE (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022)

Expectancy in placebo-controlled trials of psychedelics: if so, so what? - Butler M; Jelen L; Rucker J (Psychopharmacology, 2022)

Why Otolaryngologists Should Be Interested in Psychedelic Medicine. - Asher BF (Otolaryngologic clinics of North America, 2022)

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review. - Pouyan N; Halvaei Khankahdani Z; Younesi Sisi F; Lee Y; Rosenblat JD; Teopiz KM; Lui LMW; Subramaniapillai M; Lin K; Nasri F; Rodrigues N; Gill H; et al. (CNS drugs, 2022)

The Emerging Field of Psychedelic Psychotherapy. - Barber GS; Aaronson ST (Current psychiatry reports, 2022)

Animal Behavior in Psychedelic Research. - Odland AU; Kristensen JL; Andreasen JT (Pharmacological reviews, 2022)

Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos? - Dupuis D; Veissière S (Transcultural psychiatry, 2022)

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. - Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ (Transcultural psychiatry, 2022)

Microdosing with classical psychedelics: Research trajectories and practical considerations. - Wong A; Raz A (Transcultural psychiatry, 2022)

Potential Therapeutic Effects of Psilocybin: A Systematic Review. - Goel DB; Zilate S (Cureus, 2022)

The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier? - Mohamed A; Touheed S; Ahmed M; Hor M; Fatima S (Cureus, 2022)

THE RENAISSANCE OF PSYCHEDELICS IN PSYCHIATRY: EVIDENCE, ETHICS, AND POTENTIAL IN MENTAL HEALTH TREATMENT FOR ADOLESCENTS - Carol Vidal; Kevin M. Gray (Journal of the American Academy of Child & Adolescent Psychiatry, 2022)

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing - Dougherty RF; Clarke P; Alti M; Kuc J; Schlosser D; Dunlop BW; Hellerstein DJ; Aaronson ST; Zisook S; Young AH; Carhart-Harris R; Goodwin G; et al. (PsyArXiv, 2022)

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing - Robert F. Dougherty; Patrick Clarke; Merve Alti; Joanna Kuc; Danielle Schlosser; Boadie W. Dunlop; David J. Hellerstein; Scott T. Aaronson; Sidney Zisook; Allan H Young (PsyArXiv, 2022)

Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. - Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M (International journal of molecular sciences, 2022)

Taking the tripping out of psychedelic medicine - Elie Dolgin (Nature, 2022)

The psychedelic remedy for chronic pain - Clare Watson (Nature, 2022)

The psychedelic escape from depression - Michael Eisenstein (Nature, 2022)

Differences across sexes on head-twitch behavior and 5-HT receptor signaling in C57BL/6J mice. - Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J (Neuroscience letters, 2022)

Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU) - COMPASS Pathways (ClinicalTrials.gov, 2022)

Brain dynamics predictive of response to psilocybin for treatment-resistant depression - Vohryzek J; Cabral J; Lord L; Fernandes H; Roseman L; Nutt D; Carhart-Harris R; Deco G; Kringelbach M. (Research Square, 2022)

Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives - A Computational Study - Gomathi Saminathan; Kavitha Kandasamy; Savitha Navaneethakrishnan; Mohana Ashokkumar; Brindha Veerappan; Krishnamoorthy Bellie Sundaram; G Aghajanian; G Marek; J.-C Bque; M Imad; L Mladenovic; J Gingrich; et al. (Letters in Applied NanoBioScience, 2022)

Psychedelic drugs for psychiatric disorders. - da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M (Journal of the neurological sciences, 2022)

Psilocybin as a healer - Kavita Golia (Consciousness Spirituality & Transpersonal Psychology, 2022)

Long-term transformative effects and integration challenges of psychedelic experiences - Victor Jivanescu (Consciousness Spirituality & Transpersonal Psychology, 2022)

Neural mechanisms of psychedelic visual imagery - Stoliker D; Preller KH; Novelli L; Anticevic A; Egan GF; Vollenweider FX; Razi A. (medRxiv, 2022)

Effective connectivity of emotion and cognition under psilocybin - Stoliker D; Novelli L; Vollenweider FX; Egan GF; Preller KH; Razi A. (medRxiv, 2022)

Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample. - Mellner C; Dahlen M; Simonsson O (International journal of environmental research and public health, 2022)

Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder - Lerer B; Singh S; Botvinnik A; Shahar O; Wolf G; Yakobi C; Saban M; Salama A; Lotan A; Lifschytz T. (Research Square, 2022)

Psilocybin therapy reduces heavy drinking. - O'Leary K (Nature medicine, 2022)

Skepticism about Recent Evidence That Psilocybin "Liberates" Depressed Minds. - Doss MK; Barrett FS; Corlett PR (ACS chemical neuroscience, 2022)

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. - Barba T; Buehler S; Kettner H; Radu C; Cunha BG; Nutt DJ; Erritzoe D; Roseman L; Carhart-Harris R (BJPsych open, 2022)

Psychedelics’ binding depends on receptor mutations - special to C EN Attabey Rodríguez Benítez (C&EN Global Enterprise, 2022)

P03-21 Magic mushrooms and psilocybin: pharmacokinetics, pharmacodynamics, and clinical applications - Diana Dias da Silva; Andreia Machado Brito-da-Costa; Silveira Martins; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho (Toxicology Letters, 2022)

From neuroplasticity to psychoplasticity: Psilocybin may reverse personality disorders and political fanaticism - Henry A. Nasrallah (Current Psychiatry, 2022)

Psychedelics for Psychiatric Disorders: Promise, Not Panacea - Mitch Earleywine; Zachary Herrmann (Psychiatric Annals, 2022)

Psychedelics in the Treatment of Substance Use Disorders - Brian S. Barnett; Jeremy Weleff (Psychiatric Annals, 2022)

Therapeutic potential of serotoninergic psychedelic substances in the treatment of Obsessive Compulsive Disorder - Rodrigues J; Nombora O; Ribeiro L. (European psychiatry: the journal of the Association of European Psychiatrists, 2022)

Psychopathological descriptive model of hallucinogenic/psychedelic drugs effect in the treatment of depression and addictions - Girala N. (European psychiatry: the journal of the Association of European Psychiatrists, 2022)

Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop - National Academies of Sciences; Engineering; Medicine; Health; Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience; Nervous System Disorders. (National Academies Press (US), Washington (DC), 2022)

A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms - Chue P; Andreiev A; Bucuci E; Els C; Chue J. (European psychiatry: the journal of the Association of European Psychiatrists, 2022)

Interplay of hydrogen bonding in deciding the conformers of psilocin: Computational insights - Bhadoria P; Venkatnarayan R. (Authorea Preprints, 2022)

Association of Psilocybin Use in Adolescents with Major Depressive Episode - Shah K; Trivedi C; Kamrai D; Akbar M; Tankersley W. (European psychiatry: the journal of the Association of European Psychiatrists, 2022)

P03-18 Simultaneous detection and quantification of psilocybin and psilocin by gas chromatography coupled to mass spectrometry (GC-MS) - Brito-da-Costa A.M.; Madureira-Carvalho A.; Dinis-Oliveira R.J.; Silva D. Dias da (Toxicology Letters, 2022)

The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research. - Lehto RH; Miller M; Sender J (Journal of holistic nursing: official journal of the American Holistic Nurses' Association, 2022)

Magic mushroom extracts in lipid membranes. - Nguyen TQT; Lund FW; Zanjani AAH; Khandelia H (Biochimica et biophysica acta. Biomembranes, 2022)

Natural language signatures of psilocybin microdosing. - Sanz C; Cavanna F; Muller S; de la Fuente L; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Carrillo F; García AM; Pallavicini C; Tagliazucchi E (Psychopharmacology, 2022)

Psychedelics as preventive treatment in headache and chronic pain disorders. - Schindler EAD (Neuropharmacology, 2022)

[The use of psilocybin for treatment-resistant depression]. - Johannesdottir A; Sigurdsson E (Laeknabladid, 2022)

Use of psychedelics in the Czech Republic: results of recent population surveys. - Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V (Central European journal of public health, 2022)

Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder. - Clifton JM; Belcher AM; Greenblatt AD; Welsh CM; Cole TO; Davis AK (Journal of psychedelic studies, 2022)

Psychedelics for Alzheimer's Disease Palliative Care. - McManus KR; Patrick R; Striepe MI; Drury MJ; Ozonsi R; Forester BP; Weinberg MS (Advances in psychiatry and behavioral health, 2022)

The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. - Kurtz JS; Patel NA; Gendreau JL; Yang C; Brown N; Bui N; Picton B; Harris M; Hatter M; Beyer R; Sahyouni R; Diaz-Aguilar LD; et al. (Cureus, 2022)

Psychedelic Psychiatry - Nutt D. (European psychiatry: the journal of the Association of European Psychiatrists, 2022)

‘Shrooms for the Blues: Psilocybin to alleviate difficult-to-treat depression - Graham Zoe (Journal of High School Science, 2022)

Psychedelics as potent anti-inflammatory therapeutics - Charles D. Nichols (Neuropharmacology, 2022)

Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative - Neşe Devenot; Trey Conner; Richard Doyle (Anthropology of Consciousness, 2022)

Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test? - Mark Molumby; Keith Gaynor; Suzanne Guérin; Róisín McNamara (Journal of Humanistic Psychology, 2022)

Delix Therapeutics: psychedelics without the trip - Ken Garber (Nature Biotechnology, 2022)

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Mushroom via Amino Acid Metabolism Pathways. - Yao S; Wei C; Lin H; Zhang P; Liu Y; Deng Y; Huang Q; Xie B (Journal of fungi (Basel, Switzerland), 2022)

A-118 Psychedelic Interventions for Neuropsychological Conditions - Brian Peacock (Archives of Clinical Neuropsychology, 2022)

Molecular insights into the regulation of constitutive activity by RNA editing of 5HT serotonin receptors. - Gumpper RH; Fay JF; Roth BL (Cell reports, 2022)

Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. - Ortiz CE; Dourron HM; Sweat NW; Garcia-Romeu A; MacCarthy S; Anderson BT; Hendricks PS (Neuropharmacology, 2022)

Review of potential psychedelic treatments for PTSD. - Henner RL; Keshavan MS; Hill KP (Journal of the neurological sciences, 2022)

Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine - Jesús M. González Mariscal; Paulina E. Sosa-Cortés (Anthropology of Consciousness, 2022)

Psilocybin and the Meaning Response: Exploring the Healing Process in a Retreat Setting in Jamaica - María de Ángeles Equihua Orozco; Shana Harris (Anthropology of Consciousness, 2022)

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. - Fadahunsi N; Lund J; Breum AW; Mathiesen CV; Larsen IB; Knudsen GM; Klein AB; Clemmensen C (Translational psychiatry, 2022)

Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study - Gitte Moos Knudsen (ClinicalTrials.gov, 2022)

Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The “Velada” - Antonella Fagetti; Roberto E. Mercadillo (Anthropology of Consciousness, 2022)

Psilocybin administration - George Winter (Journal of Prescribing Practice, 2022)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. - Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E (Translational psychiatry, 2022)

Med Check: Psilocybin for OCD, Nuplazid Vote, and More - Terri D’Arrigo (Psychiatric News, 2022)

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. - Rosa WE; Sager Z; Miller M; Bernstein I; Doerner Rinaldi A; Addicott K; Ljuslin M; Adrian C; Back AL; Beachy J; Bossis AP; Breitbart WS; et al. (Journal of palliative medicine, 2022)

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. - Kopra EI; Ferris JA; Winstock AR; Young AH; Rucker JJ (Journal of psychopharmacology (Oxford, England), 2022)

Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. - Girn M; Roseman L; Bernhardt B; Smallwood J; Carhart-Harris R; Nathan Spreng R (NeuroImage, 2022)

Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD. - Brandt SD; Kavanagh PV; Westphal F; Pulver B; Schwelm HM; Whitelock K; Stratford A; Auwärter V; Halberstadt AL (Drug testing and analysis, 2022)

The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. - Polito V; Liknaitzky P (Neuroscience and biobehavioral reviews, 2022)

Postpartum depression: A role for psychedelics? - Jairaj C; Rucker JJ (Journal of psychopharmacology (Oxford, England), 2022)

Phosphate moiety in FDA-approved pharmaceutical salts and prodrugs. - Fulmali A; Bharate SS (Drug development research, 2022)

Don't be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review. - Felsch CL; Kuypers KPC (Neuroscience and biobehavioral reviews, 2022)

Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies. - Rusanen SS; De S; Schindler EAD; Artto VA; Storvik M (Current pain and headache reports, 2022)

From Mushrooms to Myolysis: A Case of Rhabdo in Psilocybin-Induced Mood and Psychotic Disorder. - Suleiman M; Basu A; Belal S; Jacob T (The Journal of nervous and mental disease, 2022)

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. - Nygart VA; Pommerencke LM; Haijen E; Kettner H; Kaelen M; Mortensen EL; Nutt DJ; Carhart-Harris RL; Erritzoe D (Journal of psychopharmacology (Oxford, England), 2022)

Mushrooms' Legal Trip: As psilocybin research ramps up, the drug's status under the law is shifting. - Makin S (Scientific American, 2022)

Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples - James A. Kaduk; Alexander M. Sherwood; Robert B. Kargbo; Kristi W. Kaylo; Poncho Meisenheimer; Nicholas V. Cozzi (Acta Crystallographica Section A Foundations and Advances, 2022)

Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. - Rootman JM; Kiraga M; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Walsh Z (Scientific reports, 2022)

Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents. - Golden CT; Chadderton P (Scientific reports, 2022)

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy - University of California; San Diego (ClinicalTrials.gov, 2022)

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: Translational implications - Shahar O; Botvinnik A; Esh-Zuntz N; Brownstien M; Wolf R; Wolf G; Lerer B; Lifschytz T. (bioRxiv, 2022)

Genetic Survey of Psilocybe Natural Products. - Dörner S; Rogge K; Fricke J; Schäfer T; Wurlitzer JM; Gressler M; Pham DNK; Manke DR; Chadeayne AR; Hoffmeister D (Chembiochem: a European journal of chemical biology, 2022)

Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines. - Glatfelter GC; Pham DNK; Walther D; Golen JA; Chadeayne AR; Baumann MH; Manke DR (ACS omega, 2022)

9 Signs You Need Help With Magic Mushrooms uk - y7fceaj128 (Zenodo (CERN European Organization for Nuclear Research), 2022)

Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder - Singh S; Botvinnik A; Shahar O; Wolf G; Yakobi C; Saban M; Salama A; Lotan A; Lerer B; Lifschytz T. (bioRxiv, 2022)

A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS. - Farley M; Tran H; Towler S; Gevorkyan J; Pearring S; Rodda LN (Journal of analytical toxicology, 2022)

Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape - Luppi AI; Hansen JY; Adapa R; Carhart-Harris RL; Roseman L; Timmermann C; Golkowski D; Golkowski D; Ranft A; Ilg R; Jordan D; Bonhomme V; et al. (bioRxiv, 2022)

Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity - Madsen MK; Petersen AS; Stenbæk DS; Sørensen IM; Schiønning H; Fjeld T; Nykjær CH; Ulv Larsen SM; Grzywacz M; Mathiesen T; Klausen IL; Overgaard-Hansen O; et al. (medRxiv, 2022)

From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q) - Zeifman R; Spriggs MJ; Kettner H; Lyons T; Rosas F; Mediano P; Erritzoe D; Carhart-Harris R. (PsyArXiv, 2022)

From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q) - Richard J. Zeifman; Meg J Spriggs; Hannes Kettner; Taylor Lyons; Fernando Rosas; Pedro Mediano; David Erritzoe; Robin Carhart-Harris (PsyArXiv, 2022)

Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis - Rajkumar RP. (Preprints.org, 2022)

Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines - Lenz Claudius; Dörner Sebastian; Trottmann Felix; Hertweck Christian; Sherwood Alexander; Hoffmeister Dirk (ChemBioChem, 2022)

Psychedelics in the treatment of unipolar and bipolar depression. - Bosch OG; Halm S; Seifritz E (International journal of bipolar disorders, 2022)

Brain dynamics predictive of response to psilocybin for treatment-resistant depression - Vohryzek J; Cabral J; Lord L; Fernandes HM; Roseman L; Nutt DJ; Carhart-Harris RL; Deco G; Kringelbach ML. (bioRxiv, 2022)

Synapses, predictions, and prediction errors: a neocortical computational study of MDD using the temporal memory algorithm of HTM - Sherif MA; Khalil MZ; Shukla R; Brown JC; Carpenter LL. (bioRxiv, 2022)

Electrical spiking of psilocybin fungi - Gandia A; Adamatzky A. (bioRxiv, 2022)

Psychedelic use in India, its pattern and personal significance - findings from an online survey - Gokul Raj (Indian Journal of Psychiatry, 2022)

Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. - McCulloch DE; Knudsen GM; Barrett FS; Doss MK; Carhart-Harris RL; Rosas FE; Deco G; Kringelbach ML; Preller KH; Ramaekers JG; Mason NL; Müller F; et al. (Neuroscience and biobehavioral reviews, 2022)

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression - Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas F; Peill JM; Giribaldi B; Erritzoe D; Nutt D; Carhart-Harris R. (PsyArXiv, 2022)

Psilocybin: A brief overview for psychiatric mental health nurse practitioners. - Fradkin D (Perspectives in psychiatric care, 2022)

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. - Kozlowska U; Nichols C; Wiatr K; Figiel M (Journal of neurochemistry, 2022)

Molecular insights into psychedelic drug action. - Slocum ST; DiBerto JF; Roth BL (Journal of neurochemistry, 2022)

Psychedelic-inspired approaches for treating neurodegenerative disorders. - Saeger HN; Olson DE (Journal of neurochemistry, 2022)

A systematic literature review of clinical trials and therapeutic applications of ibogaine. - Köck P; Froelich K; Walter M; Lang U; Dürsteler KM (Journal of substance abuse treatment, 2022)

Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. - Sakurai H; Yonezawa K; Tani H; Mimura M; Bauer M; Uchida H (Pharmacopsychiatry, 2022)

Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS. - Zhai W; Li L; Zhao J; Xiang P; Liu M; Shi Y; Dang Y (Drug testing and analysis, 2022)

The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. - Gill H; Puramat P; Patel P; Gill B; Marks CA; Rodrigues NB; Castle D; Cha DS; Mansur RB; Rosenblat JD; McIntyre RS (Psychiatry research, 2022)

Neural mechanisms underlying psilocybin's therapeutic potential - the need for preclinical in vivo electrophysiology. - Smausz R; Neill J; Gigg J (Journal of psychopharmacology (Oxford, England), 2022)

Classic Psychedelics and Human-Animal Relations. - Pöllänen E; Osika W; Stenfors CUD; Simonsson O (International journal of environmental research and public health, 2022)

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression - Sandeep M Nayak; Bilal A Bari; David Bryce Yaden; Meg J Spriggs; Fernando Rosas; Joseph M Peill; Bruna Giribaldi; David Erritzoe; David Nutt; Robin Carhart-Harris (PsyArXiv, 2022)

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls - Joseph M. Rootman; Maggie Kiraga; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P.C. Kuypers; Zach Walsh (VIUspace, 2022)

Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults - Wake Network; Inc. (ClinicalTrials.gov, 2022)

Neuroimaging in psychedelic drug development: Past, present, and future - Wall M; Harding R; Zafar R; Rabiner EA; Nutt D; Erritzoe D. (PsyArXiv, 2022)

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. - Rootman JM; Kiraga M; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Walsh Z (Scientific reports, 2022)

Neuroimaging in psychedelic drug development: Past, present, and future - Matthew B. Wall; Rebecca Harding; Rayyan Zafar; Eugenii A. Rabiner; David Nutt; David Erritzoe (PsyArXiv, 2022)

MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of Depression - J Schneider; JP Cooper; S Davies; K Beltran (Value in Health, 2022)

Classic and non-classic psychedelics for substance use disorder: A review of their historic, past and current research - Fúlvio Rieli Mendes; Cristiane dos Santos Costa; Victor Distefano Wiltenburg; Gabriela Morales-Lima; João Ariel Bonar Fernandes; Renato Filev (Addiction Neuroscience, 2022)

Associations between classic psychedelics and nicotine dependence in a nationally representative sample. - Jones G; Lipson J; Nock MK (Scientific reports, 2022)

The Neuroimaging Documentation of Psychedelic Drugs’ Effect on the Brain: dmt, lsd, Psilocybin, and Ibogaine as Examples: A Mini Review - Wahab Alahmari Abdul (Brain and Neurological Disorders, 2022)

Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience. - Viktorin V; Griškova-Bulanova I; Voicikas A; Dojčánová D; Zach P; Bravermanová A; Andrashko V; Tylš F; Korčák J; Viktorinová M; Koudelka V; Hájková K; et al. (Journal of personalized medicine, 2022)

Applying Lessons From Cannabis to the Psychedelic Highway - Kevin F. Boehnke; Alan K. Davis; Jenna McAfee (JAMA Health Forum, 2022)

Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior. - Wojtas A; Bysiek A; Wawrzczak-Bargiela A; Szych Z; Majcher-Maślanka I; Herian M; Maćkowiak M; Gołembiowska K (International journal of molecular sciences, 2022)

Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies. - Hibicke M; Nichols CD (Scientific reports, 2022)

Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions - Annie M. McCartney; H. T. McGovern; Alexander De Foe (Journal of Psychedelic Studies, 2022)

Optimization through a Box-Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (). - Polo-Castellano C; Álvarez JÁ; Palma M; Barbero GF; Ayuso J; Ferreiro-González M (Journal of fungi (Basel, Switzerland), 2022)

Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin - Anthony Principe (SURG Journal, 2022)

Association of Psilocybin Use in Adolescents with Major Depressive Episode - Kaushal Shah; C. Trivedi; D. Kamrai; M. Akbar; W. Tankersley (European Psychiatry, 2022)

Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study. - van Elk M; Fejer G; Lempe P; Prochazckova L; Kuchar M; Hajkova K; Marschall J (Psychopharmacology, 2022)

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. - Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR (Irish journal of medical science, 2022)

Serotonin toxicity of serotonergic psychedelics. - Malcolm B; Thomas K (Psychopharmacology, 2022)

Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice. - Vohra HZ; Saunders JM; Jaster AM; de la Fuente Revenga M; Jimenez J; Fernández-Teruel A; Wolstenholme JT; Beardsley PM; González-Maeso J (Psychopharmacology, 2022)

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. - Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H (Psychopharmacology, 2022)

Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. - Bender D; Hellerstein DJ (Psychopharmacology, 2022)

Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations. - Miceli McMillan R; Jordens C (Medicine, health care, and philosophy, 2022)

Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. - Müller F; Kraus E; Holze F; Becker A; Ley L; Schmid Y; Vizeli P; Liechti ME; Borgwardt S (Psychopharmacology, 2022)

The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review. - Maia LO; Beaussant Y; Garcia ACM (Journal of pain and symptom management, 2022)

The therapeutic potential of psilocybin: a systematic review. - van Amsterdam J; van den Brink W (Expert opinion on drug safety, 2022)

Effects of the 5-HT receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. - Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J (Psychopharmacology, 2022)

Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats - Popik Piotr; Hogendorf Adam; Bugno Ryszard; Khoo Shaun Yon-Seng; Zajdel Pawel; Malikowska-Racia Natalia; Nikiforuk Agnieszka; Golebiowska Joanna (Psychopharmacology, 2022)

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. - Sarparast A; Thomas K; Malcolm B; Stauffer CS (Psychopharmacology, 2022)

The promises and perils of psychedelic pharmacology for psychiatry. - McClure-Begley TD; Roth BL (Nature reviews. Drug discovery, 2022)

Development of an -based norbaeocystin production platform and evaluation of behavioral effects in rats. - Adams AM; Anas NA; Sen AK; Hinegardner-Hendricks JD; O'Dell PJ; Gibbons WJ; Flower JE; McMurray MS; Jones JA (Metabolic engineering communications, 2022)

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. - van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH (Psychopharmacology, 2022)

Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits? - Husain MI; Umer M; Mulsant BH (Expert opinion on drug safety, 2022)

Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. - Rossi GN; Hallak JEC; Bouso Saiz JC; Dos Santos RG (Expert opinion on drug safety, 2022)

3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review. - Inouye A; Wolfgang A (Cureus, 2022)

SP56 Psychedelic drugs and pain - M Rekatsina; E Moka; A Vadalouca; G Varrassi (Invited speakers, 2022)

The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder. - Manish Agrawal; Paul Thambi; Sarah Shnayder (Journal of Clinical Oncology, 2022)

Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland. - Al-Imam A; Motyka MA; Witulska Z; Younus M; Michalak M (International journal of environmental research and public health, 2022)